CAR T therapy has emerged in recent years as a feasible treatment for patients with chronic lymphocytic leukemia, but there are still many unanswered questions.
Discontinuing antibacterial therapy in neutropenic patients with acute myeloid leukemia did not lead to excessive mortality or severe infections.
An expert panel from the European LeukemiaNet discussed optimal treatment strategies for patients with acute promyelocytic leukemia.
Researchers classified 49 single-agent and 13 multiple-agent chemotherapy regimens by severity of emetogenicity.
Researchers measured levels of glucagon-like peptide-1 and C-reactive protein to determine their value as predictive biomarkers of toxicity.
GVHD prophylaxis including anti-T-lymphocyte globulin was associated with improved survival and quality of life.
Additionally, hyperferritinemia both before and after transplant was found to have negative prognostic value.
According to a study published in Blood, using a pediatric regimen for patients up to 40 years of age with acute lymphoblastic leukemia (ALL) may improve survival rates compared with historical controls. The prospective study (CALGB 10403; ClinicalTrials.gov Identifier: NCT00558519) took place from 2007 to 2012 and used the same treatment doses and schedule as…
Safety and efficacy did not differ significantly between 2 decitabine treatment schedules for acute myeloid leukemia.
Over half of patients receiving azacitidine maintenance achieved protocol completion, supporting the feasibility of this therapeutic approach.
The identification of 8 new subtypes of B progenitor acute lymphoblastic leukemia may guide the diagnosis and development of more effective targeted therapies.
Researchers found some immunobiological profiles specific to patients with acute lymphoblastic leukemia.
Researchers assessed the influence of cyclophosphamide plus etoposide on disease-free survival in patients with B-cell acute lymphoblastic leukemia.
Minimal residual disease from peripheral blood, which is easier to obtain than bone marrow, was found to correlate with some clinical outcomes.
Nonwhite race, poor acute phase nausea control, and treatment with cisplatin were all associated with higher self-reported nausea severity scores.
Patients receiving ponatinib in combination with other therapeutic agents appeared to achieve sustained responses and long-term remission.
Internal tandem duplications in FLT3 and mutations in CEBPA were independently prognostic of overall survival in patients with acute myeloid leukemia.
Results of a study on the influence of induction chemotherapy on transplant outcomes for patients with acute myeloid leukemia.
Results of a phase 3 trial of efficacy that used progression-free survival as its primary endpoint.
Measurable residual disease status can inform treatment for patients with ALL, but the optimal methods for assessment and interpretation are unclear.
Researchers evaluated the proportion of patients who had not experienced relapse at 6 months after initiation of azacitidine treatment.
The researchers reported more than 75% of patients achieved complete response after 1 cycle of the intensive chemotherapy regimen.
The overall survival probability for patients with leukemic disease was not influenced by their pretransplant levels of minimal residual disease.
A combination of alvocidib, cytarabine, and mitoxantron was found to outperform other novel treatments for relapsed/refractory acute myeloid leukemia.
Researchers retrospectively analyzed data from 508 patients with chronic myeloid leukemia who had received bone marrow aspiration or core biopsy.
Complete remission rates were higher for newly diagnosed patients on study compared with newly diagnosed patients off study.
The efficacy of inotuzumab ozogamicin in pediatric patients is less understood than in adult patients.
One of the effects of immune pathway dysregulation was decreased antigen presentation by MHC Class II genes.
For children with relapsed or refractory B-cell acute lymphoblastic leukemia, tisagenlecleucel was deemed cost-effective, yet long-term outcomes are still uncertain.
For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.
Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.
Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.
The feasibility of lenalidomide in combination therapy for chronic lymphocytic leukemia is in question.
The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.
Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.
Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.
Albumin-to-fibrinogen ratio may predict poor outcomes in patients with previously untreated chronic lymphocytic leukemia.
No direct comparison between ibrutinib and chemoimmunotherapy as a first-line treatment exists.
Researchers reveal the results of the phase 2 CLL2-BAG trial, which evaluated sequential bendamustine followed by obinutuzumab and venetoclax in patients with CLL.
A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.
In an open-label study, researchers sought to determine the optimal amount of bed rest after intrathecal chemotherapy for patients with hematologic cancers.
A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.
Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.
There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.
Quizartinib — an investigational FLT3 inhibitor — is the first agent in its class to demonstrate improved overall survival.
A retrospective chart review was conducted to determine if adding lorazepam to granisetron would improve CINV prevention in pediatric patients with newly diagnosed ALL.
High levels of CAR-T cell expansion in vivo and high pretreatment disease burden appeared to increase the likelihood that a neurotoxic event may occur following CAR-T administration.
Ivosidenib is the first-in-class FDA approval for IDH1 mutation-harboring acute myeloid leukemia.
Clinical stage determined by the Binet staging system could be an accurate response surrogate among patients with chronic lymphocytic leukemia.
For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.